Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.

The firm is looking ahead to Phase III Kimmtrak results in cutaneous melanoma and early-stage readouts from its PRAME candidates.

So far, the BCMA-targeted CAR has shown early success in four Australian multiple myeloma patients in a Phase I trial.

The startup aims to create a platform for treating extremely rare genetic mutations, armed with CRISPR advances and new regulatory pathways.

The companies will leverage Bayer's expertise in developing medicines for heart conditions and Soufflé's siRNA delivery technologies to advance the treatment.

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how politics will impact innovation long term.

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

The therapy, A2B543, will be added as an arm to the ongoing Phase I/II EVEREST-2 trial, which is testing CAR T-cell products developed using A2's Tmod platform. According to A2, the Tmod platform ...

NEW YORK – Sarepta Therapeutics on Wednesday said it submitted an application to regulators in New Zealand, seeking to begin a first-in-human trial of SRP-1005, the siRNA drug it's developing for ...

Lexeo says the collaboration will accelerate the development of an unnamed preclinical cardiac gene therapy target.

CS-101 is Shanghai-based CorrectSequence's lead candidate, which it is developing for treating sickle-cell disease and ...